- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03797339
Multi-omics Study of Clinical Endpoints in CHD (OmiDETCHD)
Multi-omics Study of the Individual Differences of Drug Efficacy and Toxicity in Patients With Coronary Heart Disease
Study Overview
Status
Conditions
Detailed Description
The study is a multicenter prospective cohort study, aimed to explore underlying mechanisms of individual differences in drugs for coronary heart disease treatment and its association with adverse consequences.The genomic genotype, DNA methylation and metabolome of 1000 patients with coronary heart disease were determined using illumina high-density genotyping chip, high-throughput sequencing and high-resolution mass spectrometry. Blood exposures of statins and metoprolol and its metabolites was determined by UPLC-MS/MS.
The biological network using cross-omics analysis was reconstructed to identify potential causative key genes, bacteria, and endogenous metabolite targets that cause differences in individual responses. A machine identification algorithm selecting clinical factors and multi-omics targets was used to establish a predictive mathematical model.
A multi-center clinical cohort of 3000 coronal heart disease patients was used to verify the effects of various levels of omic targets on drug blood exposures, efficacy and toxic side effects. A comprehensive model based on multi-target combination of individualized drugs was constructed, and the predictive effect was clinically analyzed.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Shilong Zhong, Ph.D
- Phone Number: 51157 862083827812
- Email: zhongsl@hotmail.com
Study Contact Backup
- Name: Juer Liu, master
- Phone Number: 51157 13430267895
- Email: liujesysu@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- Guangdong General Hospital
-
Contact:
- Shilong Zhong, Ph.D
- Phone Number: 8618620819696
- Email: zhongsl@hotmail.com
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- The First Affiliated Hospital of Sun Yat-sen University
-
Contact:
- Chen Liu, MD, PhD
- Phone Number: 8615013270269
- Email: chenliu81@hotmail.com
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Recruiting
- Xiangya Hospital Central South University
-
Contact:
- Qilin Ma, MD
- Phone Number: 86731-84327203
- Email: mqilin2004@163.com
-
-
Shanghai
-
Shanghai, Shanghai, China, 200233
- Recruiting
- Renji Hospital Affiliated to Shanghai Jiaotong University
-
Contact:
- Linghong Shen, MD, PhD
- Phone Number: 8613916495713
- Email: drshenlinghong@126.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- West China Hospital, Sichuan University
-
Contact:
- Liang Ouyang, PhD
- Phone Number: 8613880674611
- Email: ouyangliang@scu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age: 18-80 years
- Chinese Han patients with coronary artery disease
- inpatients undergoing coronary angiography or percutaneous coronary intervention
Exclusion Criteria:
- renal insufficiency (defined as serum creatinine concentration > 2 times the upper limit of normal [230 μmol/L], renal transplantation or dialysis)
- hepatic insufficiency (defined as serum transaminase concentration > 2 times the upper limit of normal [80 U/L], or a diagnosis of cirrhosis)
- pre-existing bleeding disorders
- being pregnant or lactating
- advanced cancer or haemodialysis
- history of thyroid problems, and use of antithyroid drugs or thyroid hormone medication
- incomplete information about cardiovascular events during follow-up
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Discovery cohort
1000 cases of coronary heart disease follow-up cohort was used for multi-omics target discovery.During the follow-up period, the information about the occurrence and risk factors of adverse cardiovascular events will be collected.
|
During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters(Lipid, hsCRP levels, etc)and other laboratory examination parameters will be collected
Genome-wide genotype , DNA methylation and metabolomes were determined using illumina high-density genotyping chips, high-throughput sequencing, and high-resolution mass spectrometry respectly.
Blood exposure of statins and metoprolol and its metabolites was determined by UPLC-MS/MS.
|
Validation corhort
3000 coronary heart disease follow-up cohorts was used for validating the results from the discovery corhort.
During the follow-up period, the occurrence and risk factors of adverse cardiovascular events.Predictive mathematical models based on multi-omics combination will be constructed finally.
|
During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters(Lipid, hsCRP levels, etc)and other laboratory examination parameters will be collected
The genome-wide genotype of patients with coronary heart disease was detected using the illumina chip.
The methylation level of the functional region was detected by the target region enrichment methylation sequencing method.
Intestinal flora differences were detected using 16SrDNA high-throughput sequencing.
Machine learning algorithms such as multiple linear regression or Bayesian classification are used to optimize clinical factors and multi-group targets to establish predictive mathematical models.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Death
Time Frame: from date of baseline examination until the date of first documented death,up to 48 months
|
All-cause death
|
from date of baseline examination until the date of first documented death,up to 48 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MACE
Time Frame: from date of baseline examination until the date of first documented cardiovascular events,up to 48 months
|
MACE was defined as the occurrence of cardiac death, nonfatal myocardial infarctions, coronary revascularisation and cerebral infraction.
|
from date of baseline examination until the date of first documented cardiovascular events,up to 48 months
|
Bleeding
Time Frame: from date of baseline examination until the date of first documented bleeding,up to 48 months
|
Bleeding was the six-month incidence of combined alarming, internal, and nuisance bleeding events defined according to Serebruany et al15.
Alarming bleeding included bleeding requiring a transfusion, intracranial bleeding, and life-threatening bleeding.
Internal bleeding included haematoma, epistaxis, blood loss from the mouth, vagina, melaena, eye bleed, haematuria, and haematemesis.
Nuisance bleeding included easy bruising, bleeding from small cuts, petechiae, and ecchymosis.
|
from date of baseline examination until the date of first documented bleeding,up to 48 months
|
Statin-induced myopathy (SIM)
Time Frame: from date of baseline examination until the date of first documented SIM,up to 48 months
|
The definition of SIM from statin treatment was based on the patients' subjective sense of muscular pain as well as CK elevations.
These muscular side effects included myalgia (muscle pain/ache without serum CK elevations), other muscle-related symptoms such as weakness, cramps, spasms, soreness and twitching, CK elevations without physical symptoms, myositis or other muscle symptoms with CK elevations, and rhabdomyolysis.
|
from date of baseline examination until the date of first documented SIM,up to 48 months
|
CI-AKI
Time Frame: more than 6 h within 48 h after Coronary Angiography
|
CI-AKI was diagnosed if a patient had an absolute increase in serum creatinine (sCr) concentration ≥ 0.3 mg/dl (26.4 μmol/L) from baseline or a relative increase ≥ 50 % in sCr concentration for more than 6 h within 48 h after surgery
|
more than 6 h within 48 h after Coronary Angiography
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SYNTAX score
Time Frame: more than 6 h within 48 h after Coronary Angiography
|
It is mainly used for the treatment of left main coronary artery lesions and/or three-vessel lesions.Patients with a score of ≥33 are recommended for CABG.
Patients with a score between 23 and 32 can choose either PCI or CABG.
Patients with a score of ≤22 are recommended for PCI and CABG.
|
more than 6 h within 48 h after Coronary Angiography
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Shilong Zhong, Ph.D, Guangdong Provincial People'S Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017YFC0909301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Heart Disease
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Shenyang Northern HospitalNot yet recruitingCoronary Heart Disease (CHD)China
-
Johns Hopkins UniversityCanon Medical Systems, USARecruiting
-
MedImmune LLCCompletedStable Coronary Heart DiseaseUnited States
-
Medical University of LodzBaxter Healthcare CorporationUnknownCHD - Coronary Heart DiseasePoland
-
University of ZurichCompletedStable Coronary Heart DiseaseSwitzerland
-
Hamad Medical CorporationMayo ClinicCompleted
-
Centro de estudios en Cardiologia IntervencionistaCompletedCoronary Heart Disease | Coronary RestenosisArgentina
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
Henan Institute of Cardiovascular EpidemiologyNot yet recruitingStable Coronary Heart Disease
Clinical Trials on risk factors of adverse cardiovascular events
-
Hospital Parc Taulí, SabadellUnknownCardiovascular Disease | Osteoarthritis | Metabolic Syndrome | Cardiovascular Risk FactorsSpain
-
Hospital de Clinicas de Porto AlegreCompleted
-
Sun Yat-sen UniversityUnknownNasopharyngeal NeoplasmsChina
-
University Hospital, MontpellierCompleted
-
University Hospital, EssenCompletedCardiovascular Diseases | Cardiovascular Risk Factor | SARSGermany
-
University of ZurichCompletedAdverse Drug ReactionsSwitzerland
-
Institut National de la Santé Et de la Recherche...Completed
-
Institut Investigacio Sanitaria Pere VirgiliWithdrawnStroke | Risk Factor, CardiovascularSpain
-
Jordan Collaborating Cardiology GroupCompletedCardiovascular Diseases | Risk FactorsJordan
-
Centre Hospitalier Régional d'OrléansRecruiting